Dear NCCN Guidelines Panel:

On behalf of Genentech, Inc., please find data from the GO30140 study enclosed for your review. This study evaluated the combination of Tecentriq™ (atezolizumab) and Avastin® (bevacizumab) for the treatment of advanced or metastatic hepatocellular carcinoma (HCC).

**Request:**
Please consider the inclusion of Tecentriq and Avastin as an initial first-line systemic treatment for patients with advanced or metastatic HCC.

**Rationale:**
Patients with advanced HCC continue to have limited treatment options. Data from the GO30140 study demonstrate activity of Tecentriq and Avastin in this patient population.¹

- In patients with unresectable or advanced HCC (n=73), treatment with Tecentriq plus Avastin resulted in an ORR of 32% per INV-assessed RECIST and 34% per IRF-assessed HCC mRECIST. Responses were observed in all assessed patient subgroups, including etiology, region, baseline alpha-fetoprotein levels and tumor burden.
- Responses were durable with 52% of patients having responses lasting ≥ 6 months and 26% lasting for ≥ 12 months.
- The safety profile of Tecentriq and Avastin was consistent with previously reported safety risks of the individual medicines.

**FDA Clearance:**
The U.S. Food and Drug Administration granted Breakthrough Therapy Designation for Tecentriq in combination with Avastin as first-line treatment for patients with advanced or metastatic HCC.²

- Tecentriq is not FDA-approved for the treatment of HCC. Please refer to the product prescribing information for the full FDA-approved indications and safety information of Tecentriq and Avastin, available at:

Any references supplied to you are protected under U.S. Copyright Law (Title 17, U.S. Code). No further reproduction is permitted.

Thank you for your consideration. If you have any questions, please contact us at the phone number and email provided above.

Respectfully submitted,
Patrice Esser, PharmD, MPH
References:
